מכפיל EV/EBITDA: Armata Pharmaceuticals, Inc. (ARMP)

The GURU.Markets price chart for Armata Pharmaceuticals (ARMP) shows an EV/EBITDA of 0.00, which correlates with its ownership of patents for bacteriophages used in the therapy of complex infections. The business relies on the genetic modification of phages to treat lungs when antibiotics prove ineffective and is implementing AI-driven automated bioscreening of candidates to accelerate preclinical trials.

Investors often overvalue biotech assets while ignoring the actual cost of capital. The EV/EBITDA metric, which assesses debt and operating leverage, compares the total enterprise value (equity plus debt) to earnings before interest, taxes, depreciation, and amortization. This indicator's trend reflects resource efficiency. Strict financial control by the Innoviva fund minimizes the risks of excessive cash burn, stabilizing the fundamental value of Armata Pharmaceuticals (ARMP).